Histogenics Corp (HSGX.OQ)

HSGX.OQ on NASDAQ Stock Exchange Capital Market

20 Nov 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company's product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue... (more)


Beta: --
Market Cap(Mil.): $49.25
Shares Outstanding(Mil.): 22.49
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

BRIEF-Histogenics Corp announces Q3 loss per share $0.23

* Histogenics Corporation announces third quarter 2017 financial and operating results

09 Nov 2017

BRIEF-Histogenics Corp promotes Stephen Kennedy to COO

* Histogenics Corporation promotes Stephen Kennedy to executive vice president & chief operating officer Source text for Eikon: Further company coverage:

12 Oct 2017

BRIEF-Histogenics says Q2 loss per share $0.25

* Histogenics corporation announces second quarter 2017 financial and operating results

10 Aug 2017

BRIEF-Histogenics on track for top-line one year superiority data, potential BLA filing in Q3 of 2018

* Histogenics completes enrollment for phase 3 clinical trial of neocart® to treat knee cartilage damage

28 Jun 2017

BRIEF-Histogenics Corp appoints Donald Haut chief business officer

* Histogenics Corporation announces the appointment of Donald Haut, Ph.D. as chief business officer Source text for Eikon: Further company coverage:

05 Jun 2017

Earnings vs. Estimates